Methamphetamine

type of chemical entity
Subclass of	DL-methamphetamine, 1-phenylpropan-2-amine alkaloid
Get use	drug, Medication
Nickname	Hermann-Göring-Pille, Cristal, polboron
Conjugate acid	methamphetamine(1+)
Stereoisomer of	L-methamphetamine
Chemical formula	C₁₀H₁₅N
Canonical SMILES	CC(CC1=CC=CC=C1)NC
Isomeric SMILES	C[C@@H](CC1=CC=CC=C1)NC
Active ingredient in	Desoxyn
World Health Organisation international non-proprietary name	metamfetamine
Found insyd taxon	Senegalia berlandieri, Vachellia rigidula
Medical condition treated	attention deficit hyperactivity disorder, obesity, narcolepsy
Significant drug interaction	isocarboxazid, phenelzine, procarbazine, (±)-deprenyl, tranylcypromine
Physically dey interact plus	solute carrier family 6 member 3, Solute carrier family 6 member 2
Pregnancy category	US pregnancy category C
NCI Thesaurus ID	C61840

Methamphetamine (dem contract from N-methylamphetamine) be a potent central nervous system (CNS) stimulant wey dem mainly use as a recreational anaa performance-enhancing drug den less commonly as a second-line treatment for attention deficit hyperactivity disorder (ADHD).^[1] Na dem sanso research am as a potential treatment for traumatic brain injury.^[2] Na dem discover Methamphetamine insyd 1893 wey e dey exist as two enantiomers: levo-methamphetamine den dextro-methamphetamine. Methamphetamine properly dey refer to a specific chemical substance, de racemic free base, wich be an equal mixture of levomethamphetamine den dextromethamphetamine insyd dema pure amine forms, buh de hydrochloride salt, dem commonly call crystal meth, dem widely be used. Methamphetamine be rarely prescribed over concerns wey dey involve ein potential for recreational use as an aphrodisiac den euphoriant, among oda concerns, as well as de availability of safer substitute drugs plus comparable treatment efficacy such as Adderall den Vyvanse.^[1] While pharmaceutical formulations of methamphetamine insyd de United States be labeled as methamphetamine hydrochloride, dem dey contain dextromethamphetamine as de active ingredient.^[1] Dextromethamphetamine be a stronger CNS stimulant dan levomethamphetamine.^[1]

Methamphetamine dey belong to de substituted phenethylamine den substituted amphetamine chemical classes. E dey relate to de oda dimethylphenethylamines as a positional isomer of dese compounds, wich dey share de common chemical formula C10H15N.

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Moszczynska A, Callan SP (September 2017). "Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment". The Journal of Pharmacology and Experimental Therapeutics. 362 (3): 474–488. doi:10.1124/jpet.116.238501. PMC 11047030. PMID 28630283. METH is a schedule II drug, which can only be prescribed for attention deficit hyperactivity disorder (ADHD), extreme obesity, or narcolepsy (as Desoxyn; Recordati Rare Diseases LLC, Lebanon, NJ), with amphetamine being prescribed more often for these conditions due to amphetamine having lower reinforcing potential than METH (Lile et al., 2013). ...
As discussed earlier, the d-enantiomer has stronger CNS effects but is metabolized more quickly than the l-enantiomer, which is longer lasting due to the slower breakdown. ...
l-METH, a vasoconstrictor, is the active constituent of the Vicks Inhaler decongestant (Proctor & Gamble, Cincinnati, OH), an over-the-counter product containing about 50 mg of the drug (Smith et al., 2014). Desoxyn, which is d-METH, is rarely medically prescribed due to its strong reinforcing properties. Therapeutic doses of Desoxyn are 20–25 mg daily, taken every 12 hours, with dosing not exceeding 60 mg/day
↑ Rau T, Ziemniak J, Poulsen D (January 2016). "The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury". Progress in Neuro-psychopharmacology & Biological Psychiatry. 64: 231–236. doi:10.1016/j.pnpbp.2015.02.013. ISSN 0278-5846. PMID 25724762.

Read further

Hart CL, Marvin CB, Silver R, Smith EE (February 2012). "Is cognitive functioning impaired in methamphetamine users? A critical review". Neuropsychopharmacology. 37 (3): 586–608. doi:10.1038/npp.2011.276. ISSN 0893-133X. PMC 3260986. PMID 22089317.
Rusyniak DE (August 2011). "Neurologic manifestations of chronic methamphetamine abuse". Neurologic Clinics. 29 (3): 641–655. doi:10.1016/j.ncl.2011.05.004. PMC 3148451. PMID 21803215.
Szalavitz M (21 November 2011). "Why the Myth of the Meth-Damaged Brain May Hinder Recovery". Time. Archived from the original on 22 September 2024. Retrieved 22 September 2024.

External links

"Methamphetamine". Drug Enforcement Administration (DEA).
"Methamphetamine". Erowid.
"Methamphetamine". National Institute on Drug Abuse (NIDA).
Methamphetamine Poison Information Monograph
Drug Trafficking: Aryan Brotherhood Methamphetamine Operation Dismantled, FBI

[d-meth_review-1] 1.0 ^1.1 ^1.2 ^1.3 Moszczynska A, Callan SP (September 2017). "Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment". The Journal of Pharmacology and Experimental Therapeutics. 362 (3): 474–488. doi:10.1124/jpet.116.238501. PMC 11047030. PMID 28630283. METH is a schedule II drug, which can only be prescribed for attention deficit hyperactivity disorder (ADHD), extreme obesity, or narcolepsy (as Desoxyn; Recordati Rare Diseases LLC, Lebanon, NJ), with amphetamine being prescribed more often for these conditions due to amphetamine having lower reinforcing potential than METH (Lile et al., 2013). ...
As discussed earlier, the d-enantiomer has stronger CNS effects but is metabolized more quickly than the l-enantiomer, which is longer lasting due to the slower breakdown. ...
l-METH, a vasoconstrictor, is the active constituent of the Vicks Inhaler decongestant (Proctor & Gamble, Cincinnati, OH), an over-the-counter product containing about 50 mg of the drug (Smith et al., 2014). Desoxyn, which is d-METH, is rarely medically prescribed due to its strong reinforcing properties. Therapeutic doses of Desoxyn are 20–25 mg daily, taken every 12 hours, with dosing not exceeding 60 mg/day

[2] Rau T, Ziemniak J, Poulsen D (January 2016). "The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury". Progress in Neuro-psychopharmacology & Biological Psychiatry. 64: 231–236. doi:10.1016/j.pnpbp.2015.02.013. ISSN 0278-5846. PMID 25724762.

[1]

[2]

Authority control databases
International	FAST
National	Germany United States France BnF data Spain Israel
Other	NARA